- Home
- RGC vs RYTM Comparison
RGC vs RYTM Comparison
Compare RGC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- RYTM
- Stock Information
- Founded
- RGC 2014
- RYTM 2008
- Country
- RGC Hong Kong
- RYTM United States
- Employees
- RGC N/A
- RYTM N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- RGC Health Care
- RYTM Health Care
- Exchange
- RGC Nasdaq
- RYTM Nasdaq
- Market Cap
- RGC 6.6B
- RYTM 6.9B
- IPO Year
- RGC 2021
- RYTM 2017
- Fundamental
- Price
- RGC $14.70
- RYTM $96.22
- Analyst Decision
- RGC
- RYTM Strong Buy
- Analyst Count
- RGC 0
- RYTM 13
- Target Price
- RGC N/A
- RYTM $101.92
- AVG Volume (30 Days)
- RGC 278.7K
- RYTM 569.8K
- Earning Date
- RGC 10-24-2025
- RYTM 11-04-2025
- Dividend Yield
- RGC N/A
- RYTM N/A
- EPS Growth
- RGC N/A
- RYTM N/A
- EPS
- RGC N/A
- RYTM N/A
- Revenue
- RGC N/A
- RYTM $156,287,000.00
- Revenue This Year
- RGC N/A
- RYTM $44.69
- Revenue Next Year
- RGC N/A
- RYTM $63.53
- P/E Ratio
- RGC N/A
- RYTM N/A
- Revenue Growth
- RGC N/A
- RYTM 53.55
- 52 Week Low
- RGC $0.09
- RYTM $45.91
- 52 Week High
- RGC $83.60
- RYTM $106.52
- Technical
- Relative Strength Index (RSI)
- RGC 54.56
- RYTM 47.02
- Support Level
- RGC $13.06
- RYTM $97.47
- Resistance Level
- RGC $13.75
- RYTM $102.46
- Average True Range (ATR)
- RGC 1.14
- RYTM 3.33
- MACD
- RGC 0.20
- RYTM -1.33
- Stochastic Oscillator
- RGC 57.47
- RYTM 0.68
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.